öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÂíÑà
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º284

ËùÊôԺУ£º¹ãÖÝÖÐÒ½Ò©´óѧ
ËùÊôԺϵ£º202ÖÐҩѧԺ
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º Ò©ÎïÖƼÁмÁÐÍÓëм¼Êõ¡¢ÐÂÒ©Ñо¿Ó뿪·¢
Ñо¿ÁìÓò£º Ò©ÎïÖƼÁмÁÐÍÓëм¼Êõ¡¢ÐÂÒ©Ñо¿Ó뿪·¢ [ÊÕÆð]




¸öÈ˼òÊö :
¸öÈ˼òÊö
1977Äê9Ô³öÉú£¬¸ÊËྲÄþÏØÈË£¬ºº×壬Öй²²úµ³Ô±£¬²©Ê¿£¬½ÌÊÚ£¬²©Ê¿Ñо¿Éúµ¼Ê¦¡£
Ö÷ÒªÈÙÓþ
2010Äê¹ãÖÝÖÐÒ½Ò©´óѧÇàÄê¿Æ¼¼±ê±ø
Ö÷ÒªÂÛÎÄ£¨ÒÔµÚÒ»×÷Õß·¢±íÂÛÎÄ£©

¿ÆÑй¤×÷ :
¹¤×÷¾­Àú
2006Äê7ÔÂÖÁ2012Äê12ÔÂÔÚ¹ãÖÝÖÐÒ½Ò©´óѧÖÐҩѧԺ¹¤×÷¡£Æä¼ä£¬2010Äê1Ô½úÉýΪ¸±½ÌÊÚ¡£
2012Äê12ÔÂÖÁ2013Äê12ÔÂÔÚÃÀ¹ú±±¿¨ÂÞÀ³ÄÉ´óѧ½ÌÌÃɽ×ö·ÃÎÊѧÕß¡£
2013Äê12ÔÂÖÁ½ñ£¬ÔÚ¹ãÖÝÖÐÒ½Ò©´óѧÖÐҩѧԺ¹¤×÷£¬2017Äê1Ô½úÉýΪ½ÌÊÚ¡£
ѧÊõ¼æÖ°
¹ã¶«Ê¡Ò½Ò©ºÏ¹æ´Ù½ø»áÌØƸר¼Ò
¿ÆÑÐÏîÄ¿
1.Ò»ÖÖÖƱ¸·½·¨¼òµ¥µÄ´Ì¼¤ÏìÓ¦ÐÍË«¹¦Äܸ´ºÏÄÉÃ×Ò©ÎïÖƼÁµÄÑо¿£¨¹ã¶«Ê¡¿Æ¼¼¼Æ»®ÏîÄ¿2016A**£¬2016/06-2019/05£¬Ö÷³Ö£©
2.»ùÓÚ¸ÄÉÆÄÑÈÜÐÔÒ©Îï¼°ÆäÖƼÁ¿Ú·þÉúÎïÀûÓöȵÄм¼ÊõÑо¿£¨¹ã¶«Ê¡¿Æ¼¼¼Æ»®ÏîÄ¿2014A**£¬2015/06-2018/05£¬Ö÷³Ö£©
3.¶à¹¦ÄÜÑ»µ¨×ÓÓÍ·Ö×ÓÅäÐÍ×é×°ÄÉÃ×ÈéÄæתÖ×Áö¶àÒ©ÄÍÒ©µÄÑо¿£¨¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿**£¬2015/01-2017/12£¬Ö÷³Ö£©
4.¸´·½×Ïɼ´¼¶à¹¦ÄÜÄÉÃ׸øҩϵͳ°ÐÏòÄæתÖ×Áö¶àÒ©ÄÍÒ©ÐÔµÄÑо¿£¨¹ã¶«Ê¡Ò½Ñ§¿ÆÑлù½ðA**£¬2015/07-2017/06£¬Ö÷³Ö£©
5.¶à¹¦ÄÜÄÉÃ׸øҩϵͳ¿¹Ö×Áö¼°ÄæתÖ×Áö¶àÒ©ÄÍÒ©ÐԵķÖ×Ó»úÖÆÑо¿£¨¹ãÖÝÖÐÒ½Ò©´óѧ¡°ÇàÄêÓ¢²ÅÅàÑø¹¤³Ì¡±QNYC**£¬2015/01-2018/12£¬Ö÷³Ö£©
6.¶à¹¦ÄÜ·Ö×ÓÅäÐÍ×é×°ÄÉÃ׸øҩϵͳ¿¹Ö×Áö·Ö×Ó»úÖƵÄÑо¿£¨¹ãÖÝÖÐÒ½Ò©´óѧ¡°Ð½»ð¼Æ»®¡±×ÊÖúÏîÄ¿XH**£¬2014/11-2016/12£¬Ö÷³Ö£©
7.£¨¶ùͯ£©Î¬D¸Æ¾×½ÀƬÑо¿£¨ºáÏò¿Æ¼¼ºÏ×÷ÏîÄ¿KHC112111K07£¬2011-2013Ö÷³Ö£©
8.µ¤ºì»¯ðö¿Ú·þÒº·ÀÖÎÌÇÄò²¡ÊÓÍøĤ²¡±äµÄ×÷ÓûúÖÆÑо¿£¨¹ã¶«Ê¡¹ãÖÝÊпÆОÖÏîÄ¿2013J**£¬2013/05-2016/05£¬ÅÅÃûµÚÈý£©
9.èÖƤËصÎÑÛÒºÓÃÓÚÖÎÁÆÌÇÄò²¡ÊÓÍøĤ²¡±äµÄ¿ª·¢Ñо¿£¨¹ã¶«Ê¡¿Æ¼¼¼Æ»®ÏîÄ¿2011B**£¬2011/09-2013/09£¬ÅÅÃûµÚ¶þ£©
10.»ùÓÚθ³¦×ªÔ˺ÍÉúÀíÒ©¶¯Ñ§Ä£ÐÍ̽Ë÷ÖÐÒ©¸´·½×é·ÖÅäÎéÏ໥×÷ÓùæÂɼ°»úÖÆ£¨¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð**£¬2009/09-2012/09£¬ÅÅÃûµÚ¶þ£©
Ö÷ÒªÂÛÎÄ
1.ExtremeLowDoseof5-FluorouracilReversesMDRinCancerbySensitizingCancerAssociatedFibroblas,PlosOne,?2017,?12(6):e**.
2.Terbinafine:NovelFormulationsThatPotentiateAntifungalActivities.DrugsofToday,2015,51(3):197-208.
3.EnhancementoftheOralBioavailabilityofBreviscapinebyNanoemulsionsDrugDeliverySystem£¬DrugDevelopmentandIndustrialPharmacy£¬2015£¬41(2)£º177-182.
4.CombinationaldeliveryofHydrophobicandHydrophilicAnticancerDrugsinSingleNanoemulsionstoTreatMDRinCancer£¬MolecularPharmaceutics£¬2014£¬11£º2623-2630.
5.Characteristicsandevaluationofaninjectableclarithromycinlipid-basedcomplexinvitroandinvivo£¬DrugDelivery£¬2013£¬20(8)£º349-355.
6.Newmousexenograftmodelmodulatedbytumor-associatedfibroblastsforhumanmulti-drugresistanceincancer.OncologyReports,201534(5):2699-2705.
7.Preparationandevaluationofthesoliddispersionsofpoorlysolublesilybin.JournalofChinesepharmaceuticalsciences.2011,20:604-608.
8.èÖƤËØ´óÊóÔÚÌ峦ÎüÊÕ¶¯Á¦Ñ§µÄÑо¿.ÖгÉÒ©.2012,34(8):74-76.
9.º£ÔåËá¸ÆÄý½ºÎ¢ÍèÊÍÒ©»úÖƵĿ¼²ì.ÖйúҩѧÔÓ.2009,44(20):1564-1566.
10.¡¶Ò©Óø߷Ö×Ó²ÄÁÏѧ¡·´´ÐÂÐÍʵÑé½ÌѧµÄ̽Ë÷.½ÌÓý½ç,2015,9:104.
11.»ùÓÚCBI½ÌѧÀíÄîµÄ¡¶ÖÐÒ©Ò©¼Áѧ¡·Ë«Óï½Ìѧ̽Ë÷.ÖйúÖÐÒ½Ò©ÏÖ´úÔ¶³Ì½ÌÓýÔÓÖ¾Éç2014,12(17):90-91.
12.Evaluationoftetrandrinesustainedreleasecalciumalginategelbeadsinvitroandinvivo.YakugakuZasshi£¬2009£¬129£¨7£©£º851-854.
13.LC/MS/MSquantitationassayforpharmacokineticsofnaringeninanddoublepeaksphenomenoninratsplasma.InternationalJournalofPharmaceutics.2006,307(2)£º292-299.
14.·Û·À¼º¼îº£ÔåËá¸Æ»ºÊÍÄý½ºÎ¢ÍèµÄÖƱ¸.ÖÐÒ©²Ä£¬2008£¬31£¨1£©£º131-134.
15.Ò©ÀíʵÑéÖÐCaco-2ϸ°ûÄ£Ðͽ¨Á¢µÄÆÀ¼ÛÖ¸±ê.ÖÐÒ©²Ä£¬2006,29(9)£º946-948.
16.HPLC·¨²â¶¨È®Ñª½¬Öз۷À¼º¼îµÄº¬Á¿.ÖÐÒ©²Ä£¬2008£¬31£¨9£©£º1426-1427.
17.·Û·À¼º¼îº£ÔåËá¸Æ»ºÊÍÄý½ºÎ¢ÍèÌåÍâÊÍÒ©»úÖƵĿ¼²ì.ÖйúÖÐÒ©ÔÓÖ¾£¬2009£¬34£¨3£©£º42-44.
18.ÑÎËáÇúÂí¶à»ºÊÍƬµÄ´¦·½Ó빤ÒÕÓÅ»¯.ÖйúҽԺҩѧÔÓÖ¾£¬2009£¬29(12)£º999-1002
19.·Û·À¼º¼î»ºÊÍÄý½ºÎ¢ÍèÔÚÈ®ÌåÄÚµÄÒ©¶¯Ñ§Ñо¿.ÖйúÒ©·¿£¬2009£¬20£¨21£©£º1616-1617

½ÌÓý±³¾° :
1996Äê9ÔÂÖÁ2000Äê6ÔÂÓÚÉòÑôÒ©¿Æ´óѧҩÎïÖƼÁöλÔÓéÀֵǼÈë¿ÚÏÂÔØѧϰ£¬»ñѧʿѧλ¡£
2000Äê7ÔÂÖÁ2003Äê6ÔÂÓÚÉòÑôÒ©¿Æ´óѧҩ¼ÁѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØѧϰ£¬»ñ˶ʿѧλ¡£
2003Äê7ÔÂÖÁ2006Äê6ÔÂÓÚÉòÑôÒ©¿Æ´óѧҩ¼ÁѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØѧϰ£¬»ñ²©Ê¿Ñ§Î»¡£